Baird analyst Michael Ha raised the firm’s price target on Alignment Healthcare to $11 from $10 and keeps an Outperform rating on the shares. The firm said it is thei Top Pick and is one of the most underappreciated stories in their coverage and believe several factors including its Star Ratings advantage in California and Best-in-class cost structure, should drive significant upside on earnings growth over the coming years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare price target raised to $10 from $8 at Piper Sandler
- Alignment Healthcare price target raised to $10 from $8 at TD Cowen
- Alignment Healthcare price target raised to $7 from $4.50 at Barclays
- Alignment Healthcare sees FY24 revenue $2.61B-$2.64B, consensus $2.52B
- Alignment Healthcare sees Q3 revenue $655M-$665M, consensus $630.25M